1. Home
  2. SANW vs MEIP Comparison

SANW vs MEIP Comparison

Compare SANW & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SANW
    SELLHOLDBUYas of a day ago
  • MEIP
    SELLHOLDBUYas of a day ago
  • Stock Information
  • Founded
  • SANW 1980
  • MEIP 2000
  • Country
  • SANW United States
  • MEIP United States
  • Employees
  • SANW N/A
  • MEIP N/A
  • Industry
  • SANW Farming/Seeds/Milling
  • MEIP Biotechnology: Pharmaceutical Preparations
  • Sector
  • SANW Consumer Staples
  • MEIP Health Care
  • Exchange
  • SANW Nasdaq
  • MEIP Nasdaq
  • Market Cap
  • SANW 18.8M
  • MEIP 17.1M
  • IPO Year
  • SANW 2010
  • MEIP 2003
  • Fundamental
  • Price
  • SANW $7.05
  • MEIP $2.18
  • Analyst Decision
  • SANW Strong Buy
  • MEIP Hold
  • Analyst Count
  • SANW 1
  • MEIP 2
  • Target Price
  • SANW $35.00
  • MEIP $7.00
  • AVG Volume (30 Days)
  • SANW 6.1K
  • MEIP 8.4K
  • Earning Date
  • SANW 05-13-2025
  • MEIP 05-08-2025
  • Dividend Yield
  • SANW N/A
  • MEIP N/A
  • EPS Growth
  • SANW N/A
  • MEIP N/A
  • EPS
  • SANW N/A
  • MEIP N/A
  • Revenue
  • SANW $54,809,365.00
  • MEIP N/A
  • Revenue This Year
  • SANW N/A
  • MEIP N/A
  • Revenue Next Year
  • SANW $14.25
  • MEIP N/A
  • P/E Ratio
  • SANW N/A
  • MEIP N/A
  • Revenue Growth
  • SANW N/A
  • MEIP 33.76
  • 52 Week Low
  • SANW $2.10
  • MEIP $2.15
  • 52 Week High
  • SANW $11.60
  • MEIP $4.10
  • Technical
  • Relative Strength Index (RSI)
  • SANW 40.48
  • MEIP 27.69
  • Support Level
  • SANW $6.73
  • MEIP $2.28
  • Resistance Level
  • SANW $7.24
  • MEIP $2.35
  • Average True Range (ATR)
  • SANW 0.60
  • MEIP 0.07
  • MACD
  • SANW -0.05
  • MEIP -0.01
  • Stochastic Oscillator
  • SANW 18.90
  • MEIP 0.00

Stock Price Comparison Chart: SANW vs MEIP

SANW
MEIP
JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025April01020304050607080SANW VS MEIP

About SANW S&W Seed Company (NV)

S&W Seed Co is a multi-crop, middle-market agricultural company. It is engaged in the breeding, production, and sale of alfalfa seed and sorghum seed. It also has a growing commercial market presence in sunflower and maintains an active stevia development program. The company's seed platform develops and supplies germplasm designed to produce higher yields for farmers globally. Its geographical segments include the United States, Australia, Saudi Arabia, Mexico, South Africa, and other countries. Maximum of revenue is earned from USA following Australia second and Mexico third.

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use